Biomarkers of depression in individuals with both MS and depression to guide management

There is a lack of data examining the biomarkers (objective signs) of depression in people with MS. This pilot study will be the first to provide longitudinal information over time on the treatment of depression and associated reductions in specific biomarkers in individuals newly diagnosed with MS and depression. These findings will provide support for the treatment of depression as an important disease-modifying therapeutic strategy, as well as a symptomatic treatment for individuals with MS.

Greater understanding of the role of inflammation is important to enhance our understanding of the causes and subsequent resulting damage of depression, with the aims of early intervention and personalised therapy in individuals with MS. If certain biomarkers are found to reduce or increase as a result of a certain psychology treatment, this could contribute to improvements in mental health and quality of life for people with MS. It could also allow for the prevention of depressive episodes, timely mental health interventions and assist in improving treatment decisions, improved diagnosis, tracking progression and determining response to therapy.